Twirla (Levonorgestrel/Ethinyl Estradiol)
Brand Names: Twirla
Methodology & AI Transparency ⓘ
Twirla (Levonorgestrel/Ethinyl Estradiol) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Twirla (Levonorgestrel/Ethinyl Estradiol) represents a prescription brand-name progestin entry registered by Agile Therapeutics, Inc.
- 2 Real-world patient consensus: Branded progestin presentation of Levonorgestrel/Ethinyl Estradiol (Agile Therapeutics, Inc.); generic reference: /meds/levonorgestrel-ethinyl-estradiol.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Twirla (Levonorgestrel/Ethinyl Estradiol) include nausea (9.9%), headache (8.5%), dizziness (6.5%).
Ask our AI Specialists anything about Twirla (Levonorgestrel/Ethinyl Estradiol)
Twirla (Levonorgestrel/Ethinyl Estradiol) Mechanism, CYP450 Pathways & DailyMed Monograph
Twirla (Levonorgestrel/Ethinyl Estradiol) represents a prescription brand-name progestin entry registered by Agile Therapeutics, Inc. with package codes 71671-100. Reviewed against 2026-06-30 FDA SPL standards (2.6 mg/1 / 2.3 mg/1 Patch; 0.15mg-30mcg Blister Pack of 28 Tablets), clinical deployment addresses 1 Indications and usage twirla: is indicated as a method of contraception for use in women of reproductive potential with.
Twirla achieves therapeutic action via Levonorgestrel/Ethinyl Estradiol, engaging progestin physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 2.6 mg/1 / 2.3 mg/1 Patch; 0.15mg-30mcg Blister Pack of 28 Tablets (registered by Agile Therapeutics, Inc., NDC 71671-100), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Twirla ($1696.00 retail) with generic Levonorgestrel/Ethinyl Estradiol ($640.00 low cash).
Systemic exposure to Twirla (Levonorgestrel/Ethinyl Estradiol) reflects Approximately 51% to 63% enteral uptake across labeled Twirla (Levonorgestrel/Ethinyl Estradiol) strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar twirla (levonorgestrel/ethinyl estradiol) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Twirla (Levonorgestrel/Ethinyl Estradiol) half-life window (maximum serum exposure occurs 2–5 hours after twirla (levonorgestrel/ethinyl estradiol) dosing response profile).
Dosing protocols (2.6 mg/1 / 2.3 mg/1 Patch or 0.15mg-30mcg Blister Pack of 28 Tablets or 0.15mg-0.03mg Blister Pack of 91 Tablets) balance efficacy (80.00% patient satisfaction across 5 logs) against nausea (9.9% of reports), headache (8.5% of reports), dizziness (6.5% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to twirla (levonorgestrel/ethinyl estradiol) (ndc 71671-100); severe baseline organ impairment where levonorgestrel/ethinyl estradiol accumulation exceeds safe therapeutic margins.
Reconcile eGFR-adjusted medications before escalating Twirla (Levonorgestrel/Ethinyl Estradiol) in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Twirla (Levonorgestrel/Ethinyl Estradiol) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Twirla (Levonorgestrel/Ethinyl Estradiol) (NDC 71671-100)
- Severe baseline organ impairment where Levonorgestrel/Ethinyl Estradiol accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (5 Reports)
Twirla (Levonorgestrel/Ethinyl Estradiol) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Twirla (Levonorgestrel/Ethinyl Estradiol))
Human clinical trial evidence for Twirla (Levonorgestrel/Ethinyl Estradiol) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Twirla (Levonorgestrel/Ethinyl Estradiol) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $66.7058/unit (~$2001.17/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Twirla (Levonorgestrel/Ethinyl Estradiol) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Twirla (Levonorgestrel/Ethinyl Estradiol) RxNorm Concept ID | 2396253 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $66.7058 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Twirla (Levonorgestrel/Ethinyl Estradiol) Patient Community, Cohort Filters & Dosage Logs
Deterministic Twirla (Levonorgestrel/Ethinyl Estradiol) reference combining NIH RxNorm (2396253), Medicaid NADAC ($66.7058/unit), and anonymous cohort outcomes (80% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Twirla (Levonorgestrel/Ethinyl Estradiol) community threads and patient logs by age, biological sex, dosage, and treatment duration.